| Phytosterols for dyslipidemia. | |
| | |
MedLine Citation:
|
PMID: 20592321 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The efficacy and safety of phytosterols for the management of dyslipidemia are reviewed. SUMMARY: Phytosterols have been evaluated in over 40 clinical trials. The incorporation of 2 g of phytosterols daily into margarine, mayonnaise, orange juice, olive oil, low-fat milk, yogurt, and tablets is associated with significant reductions in low-density-lipoprotein (LDL) cholesterol from baseline over 1-12 months in adults with normal or high cholesterol, in children, and in patients with type 2 diabetes mellitus. Phytosterol dosages of 1.6-3 g daily have been shown to reduce LDL cholesterol by 4.1-15% versus placebo within the first month of therapy. One meta-analysis found mean reductions of 10-11%, but results vary. Several placebo-controlled trials found that the addition of phytosterols to statin therapy was associated with reductions of 7-20% in LDL cholesterol for up to 1.5 years. Overall, phytosterols are useful for reducing LDL cholesterol in patients who cannot reach their treatment goal by diet alone or who are taking maximum tolerated doses of statins. These products offer an alternative to statins in patients who cannot take statins or whose statin dosage is restricted because of potential drug interactions or concomitant diseases. Commonly reported adverse effects are primarily gastrointestinal in nature. CONCLUSION: Phytosterol therapy produces an average 10-11% reduction in LDL cholesterol concentration, but it is unknown whether this effect persists beyond two years. Phytosterol products are well tolerated and have few drug interactions, but their long-term safety has not been established. Current evidence is sufficient to recommend phytosterols for lowering LDL cholesterol in adults. |
| | |
Authors:
|
Jennifer M Malinowski; Monica M Gehret |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 67 ISSN: 1535-2900 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-01 Completed Date: 2010-10-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 1165-73 Citation Subset: IM |
Affiliation:
|
Pharmacy Practice, Nesbitt College of Pharmacy and Nursing, Wilkes University, Wilkes-Barre, PA 18766, USA. jennifer.malinowski@wilkes.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Animals Antilipemic Agents / administration & dosage, adverse effects, therapeutic use* Child Cholesterol, LDL / blood, drug effects Clinical Trials as Topic Diabetes Mellitus, Type 2 / complications Dose-Response Relationship, Drug Dyslipidemias / drug therapy*, physiopathology Herb-Drug Interactions Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects, therapeutic use Phytosterols / administration & dosage, adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Phytosterols |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vernakalant: A novel agent for the termination of atrial fibrillation.
Next Document: Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).